Cell line · CVCL_0134
Papers159
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 159
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal circ_0000387 Is Associated With Ovarian Cancer Metastatic Regulation Through IGF2BP3-Related Signalling and Endothelial VWF Responses. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identifying Drug-Induced Metabolic Signatures in Comparative Untargeted NMR Metabolomics Using Difference Spectra. | Bioinorg Chem Appl | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fibroblast-derived gremlin-1 Is associated with ovarian cancer-cell phenotypes in co-culture models. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Let-7c-3p Suppresses Ovarian Cancer Progression by Targeting S100A6 and Inhibiting JAK-STAT Signaling. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HMGB2 Impacts Cisplatin-Induced DNA Adduct Processing in Chemoresistant Ovarian Cancer Cells. | Genes (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Malformin A1-mediated cytotoxicity in ovarian cancer cells occurs through pyroptosis and autophagy. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids. | Clin Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer. | J Ovarian Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Do G4 ligands induce mitochondrial dysfunction without ROS induction. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reprogramming Transcriptional Networks via CREB1 Lactylation at K122 Activates HMGB1-Mediated NETosis and Chemoresistance. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Universal principles of cell population growth follow from local contact inhibition. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overexpression of SLC44A4 suppresses ferroptosis and reduces lipid peroxidation via noncanonical NF-κB signaling in a NIK-dependent manner. | Ann Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP29-regulated noncanonical stabilization of the hypoxia-inducible factor-α in aggressive prostate cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MEOX1 Coordinates Autocrine-Paracrine Programs via SPHK1/S1P to Promote Lymph Node Metastasis in Ovarian Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0134/papers